A single infusion of a CRISPR gene-editing therapy cut "bad" cholesterol in half for a full year in a first-in-human trial from Cleveland Clinic, suggesting that the era of one-and-done treatments for chronic conditions is moving closer to reality. The Phase 1 study targeted patients with lipid disorders that had resisted standard treatments, and while it is early data, the durability of the effect is striking. It is a clean signal that gene editing may soon move beyond rare diseases into the everyday management of heart disease risk. Meanwhile, a disturbing link has emerged between a common joint supplement and Alzheimer's progression. Researchers at the University of Florida found that glucosamine use was associated with a greater likelihood that mild cognitive problems would accelerate. The finding does not prove causation, but it serves as a sobering reminder that "natural" and "widely used" are not synonyms for "harmless." On the pain front, a separate study from Semmelweis University explains why rheumatoid arthritis pain often persists even when inflammation is controlled, pointing to sleep disorders, depression, and obesity as hidden drivers that demand a broader treatment strategy. On a more ancient front, 1.7-billion-year-old microfossils stored in a Darwin warehouse have revealed new clues about the rise of complex life. The fossils, pulled from deep drill cores, suggest that early eukaryotes were experimenting with multicellularity far earlier than previously thought, nudging back the timeline for one of evolution's biggest leaps. In an unrelated but equally revisionist finding, DNA analysis of medieval graves in Sweden showed that many children buried alongside adults were not related to them, challenging the assumption that these were family plots and suggesting a more communal approach to child burial.